Moreover, most of the 17 genes used to construct IGRPM are related to the onset and progression of cancer and have the potential to become therapeutic targets for cancer, such as OASL [39], NR3C2 [32, 33], SAA1 [40], CXCL5 (C-X-C Motif Chemokine Ligand 5) [41], TLR3(toll-like receptor 3) [42], CLDN4 [43, 44], THRB [45], and LGR4 [46]. This evidence concerns the gene SAA1 and cancer.